121 related articles for article (PubMed ID: 32536689)
1. Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis.
Barosi G; Rosti V; Catarsi P; Villani L; Abbà C; Carolei A; Magrini U; Gale RP; Massa M; Campanelli R
Leukemia; 2021 Feb; 35(2):468-475. PubMed ID: 32536689
[TBL] [Abstract][Full Text] [Related]
2. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.
Rosti V; Massa M; Vannucchi AM; Bergamaschi G; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Guglielmelli P; Bruno E; Xu M; Hoffman R; Barosi G; ;
Blood Cells Mol Dis; 2007; 38(3):280-6. PubMed ID: 17350297
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Yigit N; Covey S; Barouk-Fox S; Turker T; Geyer JT; Orazi A
Hum Pathol; 2015 Aug; 46(8):1217-25. PubMed ID: 26093937
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.
Bogani C; Ponziani V; Guglielmelli P; Desterke C; Rosti V; Bosi A; Le Bousse-Kerdilès MC; Barosi G; Vannucchi AM;
Stem Cells; 2008 Aug; 26(8):1920-30. PubMed ID: 18511598
[TBL] [Abstract][Full Text] [Related]
5. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.
Cho SY; Xu M; Roboz J; Lu M; Mascarenhas J; Hoffman R
Cancer Res; 2010 Apr; 70(8):3402-10. PubMed ID: 20388788
[TBL] [Abstract][Full Text] [Related]
6. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Abbà C; Campanelli R; Catarsi P; Villani L; Abbonante V; Sesta MA; Barosi G; Rosti V; Massa M
PLoS One; 2019; 14(8):e0220189. PubMed ID: 31369569
[TBL] [Abstract][Full Text] [Related]
7. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.
Guglielmelli P; Bisognin A; Saccoman C; Mannarelli C; Coppe A; Vannucchi AM; Bortoluzzi S
PLoS One; 2015; 10(10):e0140445. PubMed ID: 26468945
[TBL] [Abstract][Full Text] [Related]
8. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteasome Genes Are Modulated in CD34
Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
[TBL] [Abstract][Full Text] [Related]
10. Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.
Rossi C; Zini R; Rontauroli S; Ruberti S; Prudente Z; Barbieri G; Bianchi E; Salati S; Genovese E; Bartalucci N; Guglielmelli P; Tagliafico E; Rosti V; Barosi G; Vannucchi AM; Manfredini R;
Mol Oncol; 2018 Dec; 12(12):2102-2123. PubMed ID: 30259659
[TBL] [Abstract][Full Text] [Related]
11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
13. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.
Wang X; Zhang W; Ishii T; Sozer S; Wang J; Xu M; Hoffman R
Cancer Res; 2009 Oct; 69(19):7612-8. PubMed ID: 19752087
[TBL] [Abstract][Full Text] [Related]
14. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
16. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
17. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
[TBL] [Abstract][Full Text] [Related]
18. A lasso and random forest model using flow cytometry data identifies primary myelofibrosis.
Zhang F; Wang YZ; Chang Y; Yuan XY; Shi WH; Shi HX; Shen JZ; Liu YR
Cytometry B Clin Cytom; 2024 Apr; ():. PubMed ID: 38647185
[TBL] [Abstract][Full Text] [Related]
19. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
20. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
